Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 revenue of $0, down from $0.3 million a year earlier, while diluted EPS was $0.46 versus $0.50. R&D spending increased as the Phase 3 AURORA trial advanced, widening the operating loss, while a $49.2 million fair-value gain on contingent value rights kept reported net income positive. Cash, cash equivalents and restricted cash totaled $149.3 million at quarter-end.

Core financial results

Cartesian recorded no collaboration, license or grant revenue during the quarter. The principal operating change was higher spending: R&D expense increased by $5.6 million, primarily because of the ongoing Phase 3 AURORA trial, while G&A expense rose due to higher professional and consulting fees.

Despite the wider operating loss, quarterly net income remained nearly unchanged because net other income increased to $44.9 million.

All amounts are GAAP figures. The company also reported basic EPS of $0.47, compared with $0.51 in the prior-year quarter.

Pipeline progress and clinical milestones

Descartes-08 remains the center of Cartesian’s clinical strategy. Four clinical readouts are expected over the next 12 months, led by Phase 3 AURORA data in myasthenia gravis in the first quarter of 2027.

AURORA is the most advanced and consequential program. The trial is enrolling approximately 100 AChR antibody-positive MG patients and compares six weekly outpatient infusions of Descartes-08 with placebo, without preconditioning chemotherapy. Its primary endpoint measures the proportion of patients achieving at least a three-point improvement in the MG Activities of Daily Living score at Month 4.

The WestGene partnership adds an earlier-stage in vivo approach. It will test the mRNA used in Descartes-08 delivered through targeted lipid nanoparticles, potentially avoiding ex vivo manufacturing if successful. WestGene received an upfront payment and may receive development and commercial milestones, but the payment amounts were not disclosed.

Fair-value gains produced net income despite a wider operating loss

Cartesian’s $15.8 million quarterly net income did not result from operating profitability. The company recorded a $29.2 million operating loss, which was more than offset by $44.9 million of net other income.

The largest contributor was a $49.2 million gain from the change in fair value of the contingent value rights liability. That gain was partly offset by a $4.5 million loss on an embedded derivative, $0.9 million of interest expense and a $0.1 million warrant-liability loss. Interest income contributed $1.1 million.

This distinction is important because clinical spending continued to rise even as reported net income stayed positive. Future changes in the valuation of these liabilities could also cause earnings to fluctuate independently of pipeline execution and operating expenses.

Cash resources and financing

Cash and cash equivalents increased to $147.6 million at June 30, 2026, from $125.1 million at the end of 2025. Including $1.7 million of restricted cash, total reported cash resources were $149.3 million. The balance included the initial $50 million term loan funded under the K2 HealthVentures credit facility and $19.3 million raised year to date, after commissions and expenses, through the ATM offering program.

The company reported $52.9 million of net long-term debt at quarter-end, compared with none at the end of 2025. Cartesian expects its current cash resources to support planned operations into 2028, including completion of AURORA, the expected clinical readouts and accelerated precommercial work.

The K2 facility provides for up to $150 million, but only the initial $50 million had been funded. A second $25 million tranche is subject to clinical and financing milestones, a third $25 million tranche depends on approval and sales milestones, and an additional $50 million remains subject to K2’s discretion.

Recent insider transactions

The supplied insider transaction data showed no insider purchases during the most recent six-month period. The latest transactions with disclosed monetary amounts included three sales in January 2026 and one director purchase in December 2025; share quantities were not provided.

These transactions establish only that the disclosed trades occurred and do not, by themselves, indicate insiders’ views of Cartesian’s prospects.

Risks investors need to watch

• AURORA execution and results: The planned mid-2027 BLA filing depends on the Phase 3 program advancing as expected. Trial timing, endpoint results or regulatory requirements could alter that path.
• Concentration of upcoming milestones: Four readouts are expected through the first half of 2027. Delays or inconclusive findings in any of these programs could affect development plans.
• Rising operating costs: R&D and G&A expenses both increased, and the company is accelerating precommercial investment before any disclosed product revenue.
• Financing conditions: The first K2 tranche increased debt, while later tranches are conditional or subject to lender discretion. The ATM program also increased equity capital during the year.
• Accounting-driven earnings volatility: The quarter’s positive net income depended on a large fair-value gain rather than operating profit, making net income potentially sensitive to future liability revaluations.

Summary

Cartesian’s Q2 2026 results reflected heavier investment in its lead Phase 3 program and a wider operating loss, while a contingent value rights revaluation preserved positive reported earnings. The $149.3 million cash position extends the company’s stated runway into 2028, but investors’ primary focus now shifts to execution of AURORA and the cluster of clinical readouts expected in the first half of 2027.